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Abstract
Network meta-analysis (NMA) expands the scope of a conventional pairwise meta-analysis
to simultaneously compare multiple treatments, which has an inherent appeal for clinicians,
patients, and policy decision makers. Two recent reports have shown that the impact of
excluding a treatment on NMAs can be substantial. However, no one has assessed the
impact of excluding a trial from NMAs, which is important because many NMAs selectively
include trials in the analysis. This article empirically examines the impact of trial exclusion
using both the arm-based (AB) and contrast-based (CB) approaches, by reanalyzing 20
published NMAs involving 725 randomized controlled trials and 449,325 patients. For the
population-averaged absolute risk estimates using the AB approach, the average fold
changes across all networks ranged from 1.004 (with standard deviation 0.004) to 1.072
(with standard deviation 0.184); while the maximal fold changes ranged from 1.032 to 2.349.
In 12 out of 20 NMAs, a 1.20-fold or larger change is observed in at least one of the popula-
tion-averaged absolute risk estimates. In addition, while excluding a trial can substantially
change the estimated relative effects (e.g., log odds ratios), there is no systematic difference
in terms of changes between the two approaches. Changes in treatment rankings are
observed in 7 networks and changes in inconsistency are observed in 3 networks. We do
not observe correlations between changes in treatment effects, treatment rankings and
inconsistency. Finally, we recommend rigorous inclusion and exclusion criteria, logical
study selection process, and reasonable network geometry to ensure robustness and gen-
eralizability of the results of NMAs.
Introduction
In clinical practice, and at a wider societal level, treatment decisions need to consider all avail-
able evidence. Network meta-analysis (NMA) expands the scope of a conventional pairwise
meta-analysis to simultaneously compare multiple treatment options [1–4] by collectively syn-
thesizing direct evidence within trials and indirect evidence across trials. In the simplest case,
one may be interested in comparing two treatments A and B. Direct evidence comes from
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randomized controlled trials (RCTs) comparing A and B, while indirect evidence comes from
RCTs of either A or B versus a common comparator C. NMA has an inherent appeal for clini-
cians, patients, and policy decision makers because it enables simultaneous inference of multi-
ple treatments and strengthens inference by including indirect evidence [5].
However, meta-analysts undertaking an NMA often selectively choose trials to include in
the systematic reviews due to certain preference. For instance, some NMAs exclude trials
with placebo or no treatment due to the belief that the placebo or no treatment may vary
over time or be set in favorable conditions to appease regulatory authorities [6]; whereas
some NMAs exclude trials without a placebo- or no treatment-arm (i.e., exclude trials com-
paring solely active treatments) [7]. In addition, some NMAs may include only trials avail-
able in a particular location or time period for convenience. It is generally difficult and
tedious to include all existing trials that meet the inclusion/exclusion criteria due to some
technical issues (i.e., some trials may be published using other languages) in NMA. Intui-
tively, if the omitted trials are similar to the included trials and there is sufficient number of
included trials, the failure to include these omitted trials will only result in less information
(i.e., bigger standard errors and wider confidence intervals), but will not have any systematic
impact on the estimates. However, if the omitted trials happen to be different from the
included, or if the number of included trials is too small to provide robust estimation, then
omission of these trials may have profound influence. The exploration of impact of exclusion
of trials helps make better sense of a network meta-analysis and guide future design and con-
duct of trials and meta-analyses.
A recent publication by Mills et al. [8] investigated the impact of removing a treatment arm
(including placebo / no treatment) on the estimated effect sizes for NMAs by reanalyzing 18
NMAs, and concluded that excluding a treatment could have substantial influence on esti-
mated effect sizes. They consequently stated that selection of treatment arms should be care-
fully considered when applying NMAs. Another publication by Lin et al. [9] further explored
the sensitivity to excluding treatments using both the armed-based (AB) [1] and contrast-based
(CB) [2] NMA approaches. They found that when a treatment was removed under the CB
framework, it was also necessary to exclude the other treatment in two-arm studies that inves-
tigated the excluded treatment, while such additional exclusions were not necessary in the AB
framework. To the best of our knowledge, no previous works, thus far, have empirically stud-
ied the impact of removing a trial in NMAs.
The primary objective of this article is to obtain empirical evidence of the impact of remov-
ing a trial on the effect size estimates. We investigate both the AB [1, 4] and CB [3] (a more
general version than in [2]) NMA approaches by reanalyzing 20 published NMAs with binary
outcomes. The impact on treatment rankings and inconsistency between direct and indirect
evidence are also assessed based on the AB approach. This article is organized as follows. First,
we describe the characteristics of the 20 network meta-analyses. Second, we briefly introduce
the two NMA approaches and our procedures assessing the impact of excluding a trial. Fold
changes are used in evaluating the impact on estimated population-averaged absolute risks
from the AB approach, and changes in log odds ratios (log ORs) are used to compare the
results from the AB and CB approaches. We close with a brief discussion with some sugges-
tions for future conduct of NMAs and several limitations of our empirical study.
Materials and Methods
Data source and extraction
We reviewed the NMAs studied by Veroniki et al. [10], which searched in PubMed for articles
published between March 1997 and February 2011 in which any form of indirect comparison
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was applied, according to the articles’ titles or abstracts. The authors initially identified 817
articles and after the screening process they ended up with 40 networks. They screened the
articles according to 1) whether the networks include at least four treatments, (2) whether the
networks contain one closed loop, (3) whether indirect comparisons are included, (4) whether
the major outcomes are dichotomous, (5) whether the articles are research papers instead of
discussing / commentary papers. We selected 20 networks in our analysis. Nineteen of them
were excluded according to our inclusion criterion that each treatment should be compared in
at least two trials; otherwise, the networks are poorly connected at that treatment node. Fur-
thermore, a treatment that is only compared in one trial would disappear from the sensitivity
analysis if that trial is excluded, disabling the possibility to investigate the impact on any effect
sizes related to that specific treatment. A network by Brown et al. [11] was also excluded
because zero events were observed in many arms, which would bring bias proportional to the
rarity of the event under study [12, 13]. Finally 20 networks involving 725 randomized con-
trolled trials and 449,325 patients were selected; they are Ara 2009 [14], Baker 2009 [15], Bal-
lesteros 2005 [16], Bansback 2009 [17], Bucher 1997 [18], Cipriani 2009 [19], Eisenberg 2008
[20], Elliott 2007 [21], Govan 2009 [22], Lu 2006 [3], Lu 2009 [2], Macfayden 2005 [23], Mid-
dleton 2010 [24], Mills 2009 [25], Picard 2000 [7], Puhan 2009 [26], Thijs 2008 [27], Trikalinos
2009 [28], Wang 2010 [29], and Yu 2006 [30].
Table 1 presents the characteristics of the individual networks. Specifically, the first column
in Table 1 lists the IDs of these networks. The second column shows the author and year of
publication for each NMA. The third to the fifth columns list the type of diseases, the primary
outcomes of interest, and the multiple investigated treatments (and their abbreviations) stud-
ied in each network. We had preference of efficacy outcome over others for studies that con-
sidered more than one outcome, as was done in Veroniki et al. [10]. The sixth column presents
the number of trials and treatments contained in each network, from which we can see that
each NMA has four or more treatments and more than twice as many studies as treatments.
Networks range in size from 9 trials on 4 treatments to 111 trials on 12 treatments. The last col-
umn shows the minimum and maximum frequencies for treatments (i.e., the number of trials
that contain a treatment) for each network. For example, in the first network Ara 2009 [14],
treatments are compared in at least 3 but no more than 7 trials. The frequencies across all net-
works range from 2 to 89.
Fig 1 graphically displays the 20 networks. In each network plot, the thickness of each link
is proportional to the number of trials investigaing the relation, and the size of each treatment
node is proprotional to the number of direct comparisons that contain that treatment. Neither
the number of trials for each pairwise comparison nor the number of direct comparisons for
each treatment are balanced in all networks. The pool includes various constructions of net-
works, where one of which (i.e., Lu 2006 [3]) contains direct information for all pairwise com-
parisions while the rest do not.
Statistical models for NMA with binary data
Now, we briefly introduce both the AB and CB approaches using Bayesian hierarchical models.
The AB approach focuses on absolute risks for each treatment arm, while the CB approach
focuses on relative effects (e.g., ORs under binary case). Existing literature [1–4, 31, 32] has
explored and discussed the model assumptions and model fit of the two approaches, and two
recent discussion papers have further provided detailed comparisons on their strengths and
limitations; see [33, 34].
We consider an NMA of I trials and K treatments of interest. Since most of the trials
only compare a subset of the treatments of interest, we let Si denote the set of treatments
The Impact of Excluding Trials from NMA
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Table 1. Characteristics of the 20 network meta-analyses.






Hypercholesterolaemia Effectiveness in reducing LDL-
c.
1 Placebo; 2 Simvastatin 40 mg/day
(SIM 40); 3 Atorvastatin 80 mg/day
(ATO 80); 4 Simvastatin 80 mg/day









Pulmonary Disease (COPD> =
1)
1 Placebo; 2 Fluticasone (FLU); 3
Budesonide (BUD); 4 Salmeterol
(SAL); 5 Formoterol (FOR); 6






Dysthymia Efficacy of antidepressants in
dysthymia
1 Placebo; 2 Tricyclic antidepressant
(TCA); 3 Selective serotonin reuptake





Moderate to severe plaque
psoriasis
Efficacy—PASI 75 response
score for the treatment of
psoriasis
1 Placebo; 2 Etanercept (ETA); 3
Infliximab (INF); 4 Adalimumab (ADA);
5 Efalizumab (EFA); 6 Alefacept (ALE);





Pseudocystis carinii Number of Pseudocystis
Carinii pneumonia (prophylaxis
against Pneumocystis carinii in
HIV infected patients)
1 Aerosolized pentamidine (AP); 2
Trimethoprim-sulphamethoxazole





Unipolar major depression Efficacy—the proportion of
patients who responded to the
allocated treatment
1 Fluoxetine (FLU); 2 Sertraline (SER);
3 Citalopram (CIT); 4 Eescitalopram
(ESC); 5 Paroxetine (PAR); 6
Fluvoxamine (FVX); 7 Milnacipran
(MIL); 8 Venlafaxine (VEN); 9
Reboxetine (REB); 10 Bupropion





Smoking Smoking abstinence 1 Placebo; 2 Buprobion (BUP); 3
Nicotine gum (NG); 4 Transdermal




Hypertension Effect of antihypertensives on
incidence diabetes mellitus-
proportion of patients who
developed diabetes
1 Placebo; 2 Thiazide diuretic (TD); 3
Angiotensin- converting enzyme (ACE)
inhibitor; 4 Calcium-channel blockers
(CCB); 5 Angiotensinreceptor blockers




Stroke Death by the end of scheduled
follow up
1 Stroke ward (SW); 2 General medical
ward (GMW); 3 Mixed rehabilitation
ward (MRW); 4 Mobile stroke team
(MST); 5 Acute (semi-intensive) ward
(AW)
28 (5) 2/24
10 Lu 2006 [3] Smoking Smoking cessation 1 No contact; 2 Self-help; 3 Inidividual
counselling (IC); 4 Group counselling
(GC)
24 (4) 6/19
11 Lu 2009 [2] Gastroesophageal reflux
disease
The number of healed patients
at one or more follow-up times
1 Placebo; 2 Prokinetic agents (PA); 3
H2 receptor antagonists (H2RA); 4
H2RA double dose (H2RA-D); 5 Proton








Resolution of discharge 1 No treatment (No Trt); 2 Topical
quinolone antibiotic (TQA); 3 Topical




The Impact of Excluding Trials from NMA
PLOS ONE | DOI:10.1371/journal.pone.0165889 December 7, 2016 4 / 17
that are compared in the ith trial, whose cardinality is equal to or smaller than (in most
cases) K. Let nik be the total number of subjects, yik be the number of events, and pik be the
corresponding probability of events for the kth treatment in the ith trial. We denote all
observed data by D.
For the AB approach proposed by Zhang et al. [1, 4], it specifies yik~Bin(nik, pik), k2Si,
i = 1,. . .,I, and F−1(pik) = μk + σvik, (vi1,. . .,vik)T ~ MVN(0, RK). Here μk is the fixed treat-
ment effect for the kth treatment, σ is the standard deviation for the random effects vik, and
RK is an exchangeable correlation matrix. The population-averaged treatment-specific
Table 1. (Continued)






Heavy menstrual bleeding Efficacy as second line
treatment for heavy menstrual
bleeding—dissatisfaction at 12
months
1 “First generation” endometrial
destruction techniques (FG); 2
Hysterectomy (HYST); 3 “Second
generation” endometrial destruction




Smoking Smoking Abstinence at
approximately 4 weeks post-
target quit date (TQD)
1 Control; 2 Nicotine replacement





Pain on injection Analgecic efficacy of
proplylactic interventions for
the prevention of pain on
injection with propofol—no
pain
1 Placebo; 2 No treatment (No Trt); 3
Lidocaine (mg) given before the
injection of propofol (LIDb); 4 Lidocaine
(mg) mixed with propofol 200 mg
(LIDm); 5 Lidocaine (mg) with
tourniquet (LID+TOU); 6 Opioids (OPI);







Exacerbation in patients with
chronic obstructive pulmonary
disease
1 Placebo; 2 Long-acting beta-
agonists (BA); 3 Long-acting
anticholinergics (AC); 4 Inhaled
corticosteroids (IC); 5 Combined
treatment with a long-acting beta-





Stroke Efficacy of antiplatelet in the
prevention of serious vascular
events after transient
ischaemic attack or stroke
1 Placebo; 2 Thienopyridines
(ticlopidin or clopidogrel) + Aspirin (THI
+ASA); 3 ASA; 4 Aspirin and




Coronary artery disease Coronary artery disease—
death
1 Medical therapy (MT); 2
Percutaneous transluminal balloon
coronary angioplasty (PTCA); 3 Bare-





Catheter-related infections Catheter colonisation 1 Standard; 2 Chlorhexidine and silver
sulfadiazine + (CHSS+); 3
Benzalkonium chloride (BC); 4 Silver
iontophoretic (SIT); 5 Minocycline-
rifampicin (MI); 6 CHSS; 7 Silver alloy-
coated (SAC); 8 Silver-impregnated
(SIP); 9 Heparin-bonded (HB)
43 (9) 2/40
20 Yu 2006 [30] Cardiac surgery Cardiac ischemic
complications and mortality
1 Control; 2 Enflurane (ENF); 3
Isoflurane (ISO); 4 Halothane (HAL); 5
Sevoflurane (SEV); 6 Desflurane (DES)
14 (6) 2/14
* Network shows the author and year of each published NMA.
† Frequency reports the smallest and largest number of trials that contain a treatment in each network.
doi:10.1371/journal.pone.0165889.t001
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; k ¼ 1; . . . ; K, where ϕ() is the density function and F() is
the cumulative density function of the standard normal distribution. The ranking of treat-
ments is calculated based on πk. When the outcome has a positive interpretation (say, effi-
cacy), the posterior probability of being the best (Pbest) is P(k is the best treatment | D) =
P(rank(πk) = 1 | D); while when the outcome has a negative interpretation (say, adverse
event), it is P(k is the best treatment | D) = P(rank(πk) = K | D). The marginal ORs are then
Fig 1. Graphacial representations for the 20 NMAs. The thickness of each link is proportional to the number of trials investigaing the relation, and the
size of each treatment node is proprotional to the number of direct comparisons that contain that treatment.
doi:10.1371/journal.pone.0165889.g001
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defined as ORkl = [πk/(1 − πk)]/[πl/(1 − πl)] for a pairwise comparison between Treatments
k and l (k 6¼l). We report ORs in addition to event rates in this paper in order to be consis-
tent with the CB approach.
Zhao et al. [35] proposed methods to detect inconsistency based on the AB approach. To
measure inconsistency between Treatments k1 and k2, trials are divided into four groups: (i)
trials that include both k1 and k2, (ii) trials include k1 but not k2, (iii) trials include k2 but not
k1, (iv) trials that include neither k1 nor k2. Then the discrepancy of direct and indirect evi-













Þ. If zero is in the far tail of this posterior distribution, then
inconsistency is found. Note that each pair of treatments needs to be assessed in a separate
model and a pair with no information of group (i), (ii) or (iii) is ineligible for inconsistency
detection.
For the CB approach proposed by Lu & Ades [3], it is based on the following hierarchical
specification: logit(pik) = μi + Xikδib(i)k, where μi is the baseline effect in Trial i, Xik’s are indica-
tors for baseline treatments taking value 0 if k = b and 1 if k6¼b, and δib(i)k represents the rela-
tive random effect of Treatment k versus b(i) on log odds scale in the ith trial. In the next step,
the vector (δib(i)k) is assumed to have a |Si| − 1 dimensional normal distribution (a univariate
normal distribution if the ith trial contains two arms or a multivariate normal distribution if
the ith trial contains multiple arms) with mean vector (db(i)k) and covariance matrix VjSi   1j, i.e.,
ðdibðiÞk;k2SiÞ  MVNðd;V jSi   1jÞ. A very common V jSi  1j is a homogeneous-variance exchange-
able matrix with correlation 1/2, i.e., δib(i)k ~ N(db(i)k, σ2) and cov(δib(i)k, δib(i)h) = σ2/2. The
model in addition assumes exchangeability, i.e., dkl = dbk − dbl. Finally ORkl ¼ edkl .
Sensitivity analysis of excluding a trial
Regardless of the approaches used in the original publications of the 20 NMAs, we reanalyzed
them in this paper using both the AB and CB approaches described in the previous Section.
Five steps were applied to each NMA to analyze the impact of omission of trials on the esti-
mated treatment effects and two more steps were conducted to assess the influence on treat-
ment ranks and inconsistency. The details are as follows:
1. Fit the AB and CB NMA Bayesian hierarchical models separately to the complete data of
each NMA. For the AB approach, both absolute risks for each treatment arm and ORs for
all pairwise comparisons are recorded; while for the CB approach, only ORs are recorded.
2. Remove each trial within each NMA and reanalyze the data using both the AB and CB
approaches. Same statistical summaries are recorded as in Step 1.
3. Calculate fold changes in the estimated absolute risks (from the AB approach) to evaluate
the impact of exclusion of trials. The fold change for Treatment k from omission of Trial i is
equal to p
ðiÞ
k =pk if p
ðiÞ
k =pk > 1; otherwise it is equal to pk=p
ðiÞ
k . Here p
ðiÞ
k is the estimated
absolute risk for Treatment k after exclusion of Trial i. In other words, fold changes are
always expressed as a value greater than 1.00. Take a simple example, if a specific event rate
is 0.70 in the full network and 0.50 in the network with one trial excluded, then the change
is 0.70/0.50 = 1.40-fold; if the event rates are 0.40 and 0.60 instead in the full and incomplete
networks respectively, then the change is 0.60/0.40 = 1.50-fold. The larger the fold change
is, the larger the impact is.










CB represent the ORs estimated from
The Impact of Excluding Trials from NMA
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ORCB are around 0, then there
is subtle impact of excluding Trial i. The further they are from 0, the larger the impact of
excluding Trial i is.





ORCB through graphical tools (e.g., scatter











 of all pairwise
comparisons using all eligible trial exclusions across all networks from the AB approach is












pling technique [36] is applied to compute the 95% confidence intervals (CIs) and the p-
value for testing difference. Note that 10,000 bootstrap samples are constructed at the net-
work level; that is, each sample contains 20 resampled networks, drawn with replacement
from the original 20 networks.
6. Assess whether the best treatment and the corresponding Pbest of that treatment change
after omission of trials, using the AB approach.
7. Evaluate the influence of omission of trials on inconsistency using the AB approach.
Step 3 evaluates the impact of omission of trials on the estimated absolute risks using the
AB approach, and Steps 4 and 5 compare the results of impact based on the AB and CB
approaches. Steps 1–5 investigate the impact on treatment effects, while Steps 6–7 further
explore the influence on treatment ranks and inconsistency.
Analyses were conducted via Markov chain Monte Carlo (MCMC) methods using JAGS
[37] and the R package “rjags” [38]. The S1 Appendix provides the JAGS codes for both
approaches. The convergence of the MCMC chains was assessed by the Gelman-Rubin conver-
gence statistic [39] and a visual inspection of the chains.
Results
Fold changes in event rates estimated from the AB approach
The average and maximal fold changes for each network from the AB approach are reported
in Table 2. The average fold changes across all networks ranged from 1.004 (with standard
deviation 0.004) to 1.072 (with standard deviation 0.184); while the maximal fold changes ran-
ged from 1.032 to 2.349. In 8 of 20 networks, the maximal changes were below 1.200-fold;
while 5 of them obtained maximal changes below 1.100-fold. Mills et al. [8] suggested consid-
ering relative changes exceeding 1.20-fold as substantial. Using this threshold, 12 out of the
20 networks had relative changes larger than 1.20-fold observed in at least one of the popula-
tion-averaged absolute risk estimates. It suggests that omission of trials may have substantial
impact on the estimation.
Table 2 also summarizes the proportions of fold changes in the estimated event rates falling
in [1.00, 1.10], (1.10, 1.20], (1.20, 1.30], (1.30, 1.40], (1.40, 1.50], and (1.50, +1) intervals for
the 20 NMAs. Five networks, which were Cipriani 2009 [19], Eisenberg 2008 [20], Mills 2009
[25], Puhan 2009 [26], and Thijs 2008 [27], obtained fold changes of estimated event rates all
smaller than 1.10-fold. Fold changes in another three networks, Ballesteros 2005 [16], Elliott
2007 [21], and Macfayden 2005 [23], were all smaller than 1.20 with some larger than 1.10.
Nine networks obtained relative changes all smaller than 1.50-fold with some exceeding
1.20-fold; they were Ara 2009 [14], Baker 2009 [15], Bucher 1997 [18], Lu 2006 [3], Lu 2009
[2], Middleton 2010 [24], Picard 2000 [7], Trikalinos 2009 [28] and Wang 2010 [29]. The rest
The Impact of Excluding Trials from NMA
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three networks, i.e., Bansback 2009 [17], Govan 2009 [22] and Yu 2006 [30], contained changes
in estimated event rates larger than 1.50-fold.
We further explore the features of the three networks with fold changes larger than 1.50. In
Bansback 2009 [17], exclusion of Trials 21 and 22 led to 1.805-fold and 1.835-fold changes in
the estimated event rate for Treatment 7 (Cyclosporine), respectively. This observation is
understandable because Trials 21 and 22 were the only two trials containing Cyclosporine,
whereas the crude event rates (observed number of events / observed total number of subjects)
of Cyclosporine in the two trials were 0.200 and 0.714, respectively. Thus excluding either trial
would lead to substantial changes in estimation. In addition, exclusion of Trial 10 in this net-
work resulted in a 1.541-fold change in event rate for Treatment 8 (Methotrexate), which were
compared in only Trials 10 and 22 with sample sizes 110 and 43 and crude event rates 0.364
and 0.605, respectively. In Govan 2009 [22], Treatment 5 (Acute ward) was compared in only
Trials 25 and 26, and the exclusion of Trial 26 resulted in a fold change of value 2.349 in the
estimated event rate for Acute ward. Though crude event rates in those two trials were not sig-
nificantly different, Trial 26 contained a much larger sample size of 134 in contrast to 27 for
Trial 25. In Yu 2006 [30], Treatment 4 (Halothane) was compared in only Trials 1 and 8 with
sample sizes 253 and 14 and crude event rates 0.036 and 0.071, and Treatment 6 (Desflurane)
was compared in only Trials 11, 13 and 14 with sample sizes 80, 100, 25 and crude event rates
0.013, 0.040 and 0.000. The exclusion of Trials 1 and 13 produced 1.951-fold and 2.303-fold
changes in the estimated event rates for Treatments 4 and 6, respectively. In summary, the
most influential trials typically contain larger sample sizes among the few trials that compare
treatments with small frequencies (in other words, treatments that are compared in small
Table 2. Summary of fold changes in terms of estimated event rates using the AB approach.
Network Fold Change Proportions of fold changes within each magnitude category*
Average (sd) Maximal 1.00–1.10 1.10–1.20 1.20–1.30 1.30–1.40 1.40–1.50 >1.50
Ara 2009 [14] 1.054 (0.049) 1.215 0.836 0.145 0.018 0.000 0.000 0.000
Baker 2009 [15] 1.025 (0.030) 1.388 0.987 0.010 0.000 0.003 0.000 0.000
Ballesteros 2005 [16] 1.038 (0.034) 1.174 0.972 0.028 0.000 0.000 0.000 0.000
Bansback 2009 [17] 1.033 (0.099) 1.835 0.949 0.028 0.006 0.000 0.000 0.017
Bucher 1997 [18] 1.044 (0.052) 1.219 0.861 0.125 0.014 0.000 0.000 0.000
Cipriani 2009 [19] 1.004 (0.004) 1.057 1.000 0.000 0.000 0.000 0.000 0.000
Eisenberg 2008 [20] 1.010 (0.009) 1.057 1.000 0.000 0.000 0.000 0.000 0.000
Elliott 2007 [21] 1.034 (0.033) 1.130 0.909 0.091 0.000 0.000 0.000 0.000
Govan 2009 [22] 1.028 (0.117) 2.349 0.986 0.000 0.000 0.007 0.000 0.007
Lu 2006 [3] 1.028 (0.040) 1.241 0.948 0.042 0.010 0.000 0.000 0.000
Lu 2009 [2] 1.016 (0.035) 1.329 0.962 0.033 0.000 0.004 0.000 0.000
Macfayden 2005 [23] 1.034 (0.038) 1.156 0.904 0.096 0.000 0.000 0.000 0.000
Middleton 2010 [24] 1.035 (0.048) 1.338 0.938 0.050 0.000 0.012 0.000 0.000
Mills 2009 [25] 1.006 (0.005) 1.032 1.000 0.000 0.000 0.000 0.000 0.000
Picard 2000 [7] 1.013 (0.020) 1.222 0.988 0.009 0.003 0.000 0.000 0.000
Puhan 2009 [26] 1.028 (0.019) 1.093 1.000 0.000 0.000 0.000 0.000 0.000
Thijs 2008 [27] 1.018 (0.013) 1.044 1.000 0.000 0.000 0.000 0.000 0.000
Trikalinos 2009 [28] 1.020 (0.030) 1.336 0.988 0.008 0.000 0.004 0.000 0.000
Wang 2010 [29] 1.017 (0.035) 1.498 0.982 0.013 0.003 0.000 0.003 0.000
Yu 2006 [30] 1.072 (0.184) 2.303 0.881 0.036 0.012 0.048 0.000 0.024
* sd represents standard deviation. Cells are in bold if all fold changes in the network fall in [1.00, 1.10]; cells are italic if fold changes > 1.20. 1.00–1.10 =
[1.00, 1.10]; 1.10–1.20 = (1.10, 1.20]; 1.20–1.30 = (1.20, 1.30]; 1.30–1.40 = (1.30, 1.40]; 1.40–1.50 = (1.40, 1.50].
doi:10.1371/journal.pone.0165889.t002
The Impact of Excluding Trials from NMA
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numbers of trials) and sometimes report different crude event rates from the rest. Omission of
those trials may bring larger impact in the estimation of treatment effects, thus may influence
treatment comparison and decision making. It further implies the importance of network
geometry.









were recorded and used to compare the performance of the AB and CB









from the 20 networks across all pairwise comparisons and trial exclusions. Most of the scatters
tended to concentrate in the vicinity of the identity line, i.e., a y = x line, suggesting agreement
between the AB and CB approaches. But scatters from four networks, i.e. Bansback 2009 [17],
Macfadyen 2005 [23], Wang 2010 [29] and Yu 2006 [30], were found to deviate from the iden-
tity line and marked with colored points. The right panel excerpts scatter plots for these four
networks individually. For Bansback 2009 [17] and Yu 2006 [30], omission of trials had larger
impact from the AB approach than from the CB approach; while for Macfadyen 2005 [23] and
Wang 2010 [29], CB approach was more sensitive to excluding trials. However, only small
numbers of the points in the scatter plots were away from the identity line; more specifically,
22 out of 616 (i.e., 3.6%) in Bansback 2009 [17], 6 out of 78 (i.e., 7.7%) in Macfadyen 2005 [23],
5 out of 210 (i.e., 2.4%) in Wang 2010 [29] and 24 out of 1548 (i.e., 1.6%) in Yu 2006 [30].
These points are circled in their individual scatter plots in the right panel of Fig 2.









. Left panel pools results from the 20 networks with
scatters deviating from the identity line in color. Right panel excerpts colored scatters.
doi:10.1371/journal.pone.0165889.g002
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The Bland-Altman plot in Fig 3 further consolidates the agreement between these two





























equal to -0.001 and was drawn in black dashed line in Fig 3. The standard deviation (SD) of
the differences was 0.055 and the width of the 95% limits of agreement (drawn in grey dashed
lines) was 0.219. The narrow range of the 95% limits of agreement showed good agreement. In



















Þ. The mean difference and 95% limits of agreement are shown in
dashed lines. Four networks are highlighted in color.
doi:10.1371/journal.pone.0165889.g003
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addition, 98.2% (15597/15878) of the differences were contained in the 95% limits of agree-
ment. Thus we conclude that the CB approach agrees well with the AB approach in terms of
the impact of excluding trials. Note that the 4 excerpted networks are also highlighted in color
in the Bland-Altman plot.
Statistical testing was also conducted to compare the AB and CB approaches in addition to






















 of all pairwise comparisons and trial exclusions from all networks for the AB and CB
approaches, respectively. The estimates for ηAB and ηBC based on the current data were 0.021
and 0.021. Using the 10,000 bootstrap samples, 95% CIs for ηAB and ηBC were estimated to be
(0.014, 0.040) and (0.013, 0.038), respectively. For the hypothesis testing H0:ηAB = ηBC versus
HA: ηAB 6¼ ηBC, the p-value was calculated based on another 10,000 bootstrap samples under
the null hypothesis. It turned out that p-value = 0.156. Therefore the absolute log OR changes
under the AB approach were not statistically significantly different from those under the CB
approach.
Impact on treatment ranks and inconsistency based on the AB approach
Table 3 shows changes in the best treatment and Pbest after omission of trials. Networks
whose outcomes have negative interpretations are listed in italics. The best treatment in thir-
teen networks after omission of trials remains the same. The Pbest of that treatment is also
provided for both the full and reduced networks. For example, in Ara 2009 [14], ATO 80
ranks as the best treatment in both the full (with Pbest = 0.880) and reduced networks (with
Pbest ranging from 0.778 to 0.878). The rest seven networks show changes in the best treat-
ment. For Baker 2009 [15], BUD + FOR is the best treatment in the full network with Pbest =
0.463, while TIO is the best treatment after omission of Trials 11, 16, 17, 22, 26 or 34 with
Pbest = 0.470, 0.551, 0.448, 0.479, 0.514 and 0.445 respectively, and BUD is the best treatment
after omission of Trial 18. For Ballesteros 2005 [16], MAOI is the best treatment with
Pbest = 0.496 in the full network, but SSRI becomes the best treatment with Pbest = 0.529
after omission of Trial 18. For Lu 2009 [2], PPI-D is the best treatment in the full network
with Pbest = 0.567, but PPI becomes the best after omission of Trials 19, 22, 36 or 39 with
Pbest = 0.538, 0.523, 0.584 and 0.538 respectively. For Puhan 2009 [26], AC is the best treat-
ment in the full network with Pbest = 0.545 and CT is the best after omission of Trials 9, 19
or 33 with Pbest = 0.343, 0.405, 0.344 respectively. For Wang 2010 [29], MI is the best treat-
ment with Pbest = 0.619 in the full network but CHSS+ becomes the best with Pbest =
0.518 after omission of Trial 37. Finally for Yu 2006 [30], SEV is the best treatment with
Pbest = 0.673 in the full network while DES becomes the best with Pbest = 0.723 after omis-
sion of Trial 13.
Changes in inconsistency are also presented in Table 3. Three networks are not assessed
because omission of some trials in these networks loses information of group (i), (ii) or (iii)
for all pairs of treatments and thus disables the detection of inconsistency. For the rest sev-
enteen networks, one eligible pair for each network is assessed. Omission of trials does not
change the status of inconsistency in most networks except three (Eisenberg 2008 [20],
Thijs 2009 [27] and Trikalinos 2009 [28]). In Eisenberg 2008 [20], inconsistency between
BUP and VAR is observed after omission of Trial 61. In Thijs 2009 [27], inconsistency
between Placebo and ASA appears after omission of Trial 4. In Trikalinos 2009 [28], incon-
sistency between PTCA and BMS disappears after omission of Trials 7, 10, 17, 46, 50, 51, 53,
57 or 62.
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Discussion
It is common for NMAs to exclude specific trials and treatment arms based on diverse criteria
[8], some limitations and preferences. The impact of exclusion of treatments arms was investi-
gated in Mills et al. [8] and Lin et al. [9] empirically and substantial influence was found,
whereas the impact of exclusion of trials has not been explored before. In this paper we empiri-
cally studied this impact using 20 published networks and documented that exclusion of trials
can sometimes affect the estimation of treatment effects substantially.
Table 3. Impact on treatment ranks, probability of the best treatment, and inconsistency using the AB approach. Note: For networks in italics, the
treatment with the lowest event rate is the best treatment; for the other networks, the treatment with the highest event rate is the best treatment. -----repre-
sents that inconsistency cannot be assessed.
Network Change in the
best treatment
Change in probability of being the best treatment Change in inconsistency
Full Reduced
Ara 2009 [14] None ATO 80
(0.880)
ATO 80 (0.778–0.878) None
Baker 2009
[15]
Top three switch BUD+FOR
(0.463)
BUD + FOR (0.437–0.546); TIO (0.470, 0.551, 0.448,
0.479, 0.514, 0.445 after omission of Trials 11, 16, 17,




Top two switch MAOI
(0.496)













None MIR (0.541) MIR (0.381–0.639) None
Eisenberg
2008 [20]
None VAR (0.974) VAR (0.942–0.987) Yes (inconsistency between BUP and VAR
observed after omission of Trial 61)
Elliott 2007
[21]
None TD (0.698) TD (0.535–0.858) None
Govan 2009
[22]
None AW (0.987) AW (0.881–0.993) None
Lu 2006 [3] None GC (0.760) GC (0.554–0.907) None
Lu 2009 [2] Top two switch PPI-D
(0.567)
PPI-D (0.500–0.829); PPI (0.538, 0.523, 0.584, 0.538




None TQA (0.946) TQA (0.855–0.967) None
Middleton
2010 [24]
Top two switch MIR (0.458) MIR (0.438–0.849); FG (0.465, 0.556, 0.414, 0.492 after
omission of Trials 16, 17, 18, 20)
None





LID + TOU (0.713–0.939) None
Puhan 2009
[26]
Top two switch AC (0.545) AC (0.469–0.675); CT (0.343, 0.405, 0.344 after
omission of Trials 9, 19, 33)
None
Thijs 2008 [27] None ASA+DP
(0.715)
ASA+DP (0.582–0.802) Yes (inconsistency between Placebo and
ASA observed after omission of Trial 4)
Trikalinos
2009 [28]
None DES (0.700) DES (0.581–0.820) Yes (Inconsistency between PTCA and BMS
disappear after omission of Trials 7, 10, 17,
46, 50, 51, 53, 57, 62)
Wang 2010
[29]
Top two switch MI (0.619) MI (0.430–0.852); CHSS+ (0.518 after omission of Trial
37)
None
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We also found that exclusion of trials, which contain larger sample sizes compared with the
other trials in the comparison of treatments with sparse information and which report differ-
ent crude event rates from the rest, tend to result in larger changes in the estimation, which is
as expected. Broadly network geometry including the abundance of trials, randomized patients
for different trials and gaps of evidence in the treatment network should be taken seriously. In
addition, the changes in treatment ranks and inconsistency are not correlated with changes in
treatment effects.
Although the AB approach focuses on reporting population-averaged absolute risks and the
CB approach focuses on estimating ORs, they both are sensitive to excluding trials. Our empir-
ical study suggested that the two approaches generally agreed on the magnitude of changes in
log OR (i.e., log ORðiÞOR ), though some small disagreement were observed in 4 of the 20 networks.
This work also contributes to the call for more empirical comparison of the AB and CB
approaches [33, 34].
It has been discussed in the literature on how eligibility criteria may influence the results
and the conclusions of traditional pairwise meta-analysis [40–44]. These findings suggest that
in meta-analysis comparing multiple treatments, it is also very important to develop a rigorous
systematic review protocol with logically considered inclusion and exclusion criteria and study
selection process, such that the results from NMAs are robust and generalizable.
There are some limitations in our analysis. First, we used a selection criterion requiring
each treatment to be studied in at least two studies. The literature has no well-established cri-
terion serving this purpose. Second, though we did check the changes in evidence consis-
tency, inconsistency detection in NMA is still an open question, has problems under both
AB and CB framework, and awaits improvements [3, 35]. Third, we did not check outlying
trials in this empirical study. Methods may need to be tailored to downweight outlyingness if
needed [31].
Turning to future work, we are interested in exploring better inclusion and exclusion crite-
ria for NMAs such as the minimum number of trials required to include a treatment arm in
the NMA, and how to account for study quality in NMAs. Sufficient number of trials for each
treatment arm is required to ensure sufficient statistical power to make robust conclusion,
whereas outlying or low-quality trials should be deleted or down-weighted at the same time
[31]. These have the potential to serve as supplement to the guidance for future conduct of
NMAs and contribute to the Preferred Reporting Items for Systematic Reviews and Meta-anal-
yses (PRISMA) Extension Statement [45].
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